Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Genetics Launches New Genetic Test for Cervical Cancer Management

Published: Wednesday, July 24, 2013
Last Updated: Wednesday, July 24, 2013
Bookmark and Share
A published research study highlights the relevance of FHACT™ in screening women with high risk of cervical cancer.

Cancer Genetics, Inc. launched its proprietary cervical cancer test and is marketing the molecular product globally through its network of distribution partners. Cervical cancer is the second most common cancer in women worldwide, with 500,000 new cases annually and almost 80% of cases occurring in developing countries.

CGI’s FISH-based HPV-Associated Cancer Test (FHACT™) uses a unique combination of genetic markers to detect genetic abnormalities located at 3q, 5p, 20q and chromosome 7. A recent study concluded that these four biomarkers are associated with the severity of cervical lesions. The findings of the study, published in the July issue of Gynecologic Oncology, http://dx.doi.org/10.1016/j.ygyno.2013.06.005, support the use of FHACT™ as an aid in the screening of women with HPV-positive abnormal cervical lesions. By identifying lesions that will progress to a higher grade versus those that will regress, FHACT™ can allow for a better triage of patients before referral for colposcopy and consequently reduce the associated healthcare burden.

The test can be performed directly on Pap smear or liquid based-cytology and does not require any resampling. It is therefore an ideal fit in countries where women have reduced access to routine screening. “We think that FHACT™ will be a new tool to help identify women with high risk of progressing to cervical cancer,” says Dr. Q. Annie Hasan, Ph.D., F.N.A.Sc., Head of Department and Senior Consultant, Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India. “This is particularly important in India due to the rising incidence of cervical cancer caused by difficulty in implementation of cervical screening programs, which require repeated evaluation in large number of women.” In partnership with its distributors and collaborators, CGI will conduct workshops in India and Mexico to accelerate adoption of FHACT™ amongst the clinical community.

In industrialized countries, it is estimated that about one million women undergo colposcopy procedures each year, while only 3,700 cancer cases are actually diagnosed. The Company expects FHACT™ to aid in lowering healthcare costs and reducing the number of unwarranted colposcopies by providing genomic information of the lesion not available until now. CGI plans to make FHACT™ available in the U.S. later this year and will be working closely with several laboratories and hospitals to implement an early adoption of the test.

The design and development of FHACT™ was supported in part by a Small Business Innovation Research (SBIR) grant. In addition to cervical cancer, FHACT™ is applicable to other HPV-associated cancers. CGI is currently conducting ongoing validations with key thought leaders for head and neck cancer and anal cancer. Results from these studies are expected to be available by year end.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Genetics, Icon Partner
Cancer Genetics has partnered with Icon's Laboratory Services group to provide a range of services.
Wednesday, July 08, 2015
Cancer Genetics Inc. and Columbia University Researchers Collaborate
Collaboration aims to identify genomic signatures, biomarkers and novel treatments for MDS and AML.
Tuesday, October 14, 2014
Cancer Genetics, Roche Expand Agreement
Companies expand molecular diagnostic cancer testing in Central America and the Caribbean.
Tuesday, February 11, 2014
Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock
Cancer Genetics, Inc. announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share.
Monday, April 08, 2013
CGI and Aptiv Solutions Form Strategic Partnership Focused on Creating More Effective Clinical Trials in Oncology
Partnership to help biotechnology and pharmaceutical companies bring next generation oncology therapeutics to market in a more targeted and effective manner.
Saturday, March 26, 2011
Scientific News
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Genes For Nose Shape Found
Genes that drive the shape of human noses have been identified by a UCL-led study.
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
NIH Funds New Studies on Ethical, Legal and Social Impact of Genomic Information
Four new grants from the National Institutes of Health will support research on the ethical, legal and social questions raised by advances in genomics research and the increasing availability of genomic information.
How Did The Giraffe Get Its Long Neck?
Clues about the evolution of the giraffe’s long neck have now been revealed by new genome sequencing.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!